INSPIRE - Investigator-initiated Phase 2 Study of Pembrolizumab Immunological Response in Metastatic Solid Tumors
- Type: Cancer Genomics
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001004873 | Illumina HiSeq 2500 | 100 | |
EGAD00001006562 | Illumina HiSeq 2500 | 45 | |
EGAD00001006563 | Illumina HiSeq 2500 | 46 | |
EGAD00001006564 | Illumina HiSeq 2500 | 65 | |
EGAD00001006569 | - | ||
EGAD00001011312 | Illumina NovaSeq 6000 | 204 |
Publications | Citations |
---|---|
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer 7: 2019 72 |
20 |
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
JNCI Cancer Spectr 5: 2021 None |
9 |
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Nat Commun 12: 2021 5137 |
38 |